NYSE:COV (COV) (COV) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free COV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume3.88 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (COV) alerts: Email Address Ad InvestorPlaceYour Portfolio’s Shield Against Inflation: Gold’s Surge and AI BreakthroughsWhile gold may be thanking China for its recent growth, this sector is currently thanking Elon Musk. As crazy as it sounds, artificial intelligence just got one step closer to ushering in "the next step in human evolution"... and minting new millionaires. And it's all thanks to Musk's latest AI creation.Click to watch this device in action About (COV) Stock (NYSE:COV)Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company’s brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries. The Company’s segments include Medical Devices and United States Medical Supplies. Medical Devices includes marketing of advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. United States Medical Supplies includes products, such as nursing care, medical surgical, SharpSafety and original equipment manufacturer (OEM) products. The Company’s products include Surgical Solutions, Vascular Therapies, Respiratory and Patient Care.Read More Ad InvestorPlaceYour Portfolio’s Shield Against Inflation: Gold’s Surge and AI BreakthroughsWhile gold may be thanking China for its recent growth, this sector is currently thanking Elon Musk. As crazy as it sounds, artificial intelligence just got one step closer to ushering in "the next step in human evolution"... and minting new millionaires. And it's all thanks to Musk's latest AI creation.Click to watch this device in action COV Stock News HeadlinesMay 12, 2024 | msn.comIf you’re the rare person who hasn’t had COVID, are you a super-dodger?May 11, 2024 | msn.comNew vaccine could protect against coronaviruses that haven't even emerged yetMay 13, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.May 11, 2024 | msn.comA deadly coronavirus has resurfaced in Saudi Arabia, killing at least one patientMay 9, 2024 | msn.com2 new COVID ‘FLiRT’ variants are on the rise: Watch out for these symptomsMay 9, 2024 | msn.comHow ‘Quartet Nanocage’ vaccine developed in Cambridge, Oxford and Caltech could provide broad protection against coronaviruses - including ones we don’t know exist yetMay 9, 2024 | msn.comNovel bispecific antibodies show promise against evolving SARS-CoV-2 variantsMay 8, 2024 | msn.comTeam develops computational approach to redesign antibodies for broader effectiveness against viral pandemicsMay 13, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.May 8, 2024 | msn.comAfrica: World Health Organization Advises Updated Vaccine Composition to Tackle SARS-CoV-2 EvolutionMay 8, 2024 | msn.comScientists develop 'simple vaccine' that could prevent future pandemicsMay 7, 2024 | msn.comTransfected SARS-CoV-2 spike DNA suppresses cancer cell response to chemotherapyMay 6, 2024 | msn.com'Quartet Nanocage' vaccine found effective against coronaviruses that haven't even emerged yetMay 6, 2024 | msn.comScientists now have vaccine to fight next Covid pandemicMay 6, 2024 | msn.comResearch aims to develop vaccine against future COVID virusesMay 5, 2024 | msn.comLong-term impact of COVID-19 on body composition exploredMay 5, 2024 | msn.comHigher CO2 Levels Have a Concerning Effect on Viruses Floating Through The AirMay 3, 2024 | msn.comPhysicist Studying COVID-19 Believes He's Discovered Hints We're Living in a SimulationMay 1, 2024 | msn.comPeter Daszak testifying: The man behind EcoHealth Alliance and the COVID-19 origins controversyApril 30, 2024 | msn.comScientist who gave world the Covid sequence is locked out of his lab by ChineseApril 30, 2024 | msn.comA better COVID treatment for the immunocompromised? Researchers create a non-toxic potential alternative to PaxlovidApril 30, 2024 | msn.comStudy identifies immunity threshold for protection against COVID-19 in childrenApril 30, 2024 | msn.comNew SARS-CoV-2 KP.2 variant defies vaccines with higher spread, study warnsApril 30, 2024 | finanznachrichten.deNanoViricides, Inc.: NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected SoonApril 29, 2024 | msn.comWhat to Know About the ‘FLiRT’ Variants of COVID-19April 29, 2024 | msn.comDo SARS-CoV-2 infections cause long-term loss of smell and taste?April 29, 2024 | npr.orgQuiz: Are you smarter than an expert on how SARS-CoV-2 spreads?See More Headlines Receive COV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (COV) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/05/2014Today5/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorN/A Industry N/A Sub-IndustryHealth Care Equipment Current SymbolNYSE:COV CUSIPG2554F11 CIK1385187 WebN/A Phone+353-1-4381700FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesGary L. Ellis (Age 61)President, Chief Executive Officer Charles J. Dockendorff (Age 63)Chief Financial Officer, Executive Vice President Bryan C. Hanson (Age 50)Group President, Covidien John H. Masterson (Age 54)Senior Vice President, General Counsel Michael P. Dunford (Age 54)Senior Vice President - Human Resources James C. Clemmer (Age 53)Senior Vice President and President - Medical Supplies Business Amy A. McBride-Wendell (Age 53)Senior Vice President - Strategy and Business Development Jacqueline F. Strayer (Age 58)Senior Vice President-Corporate Communications Michael E. Tarnoff (Age 46)Senior Vice President,Chief Medical Officer Peter L. Wehrly (Age 57)Senior Vice President, Group President - Developed Markets More Executives COV Stock Analysis - Frequently Asked Questions How were (COV)'s earnings last quarter? (COV) (NYSE:COV) issued its quarterly earnings results on Wednesday, November, 5th. The healthcare company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.13. The healthcare company had revenue of $2.73 billion for the quarter, compared to analyst estimates of $2.69 billion. (COV)'s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.91 earnings per share. What other stocks do shareholders of (COV) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (COV) investors own include Pfizer (PFE), Chevron (CVX), Intel (INTC), Johnson & Johnson (JNJ), Boeing (BA), CVS Health (CVS), EMC (EMC), Gilead Sciences (GILD) and JPMorgan Chase & Co. (JPM). This page (NYSE:COV) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (COV) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.